MARKET

PROF

PROF

Profound Med Corp
NASDAQ
6.27
+0.32
+5.38%
After Hours: 6.27 0 0.00% 16:04 04/13 EDT
OPEN
5.84
PREV CLOSE
5.95
HIGH
6.29
LOW
5.84
VOLUME
46.23K
TURNOVER
--
52 WEEK HIGH
8.95
52 WEEK LOW
3.760
MARKET CAP
227.56M
P/E (TTM)
-4.4528
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PROF last week (0406-0410)?
Weekly Report · 18h ago
Weekly Report: what happened at PROF last week (0330-0403)?
Weekly Report · 04/06 09:26
Profound Medical Showcases TULSA-PRO at Key Radiology Meeting
TipRanks · 04/01 15:03
Profound Medical To Highlight Interventional MRI TULSA Procedure In Several Presentations At 2026 SIR Annual Scientific Meeting
Benzinga · 04/01 12:17
Profound Medical to showcase TULSA-PRO prostate treatment at Society of Interventional Radiology meeting
Reuters · 04/01 12:15
Incision-Free, MRI-Guided Prostate Treatment with Profound’s TULSA-PRO® to be Featured in Multiple Presentations at the Upcoming 2026 Society of Interventional Radiology Scientific Meeting
Barchart · 04/01 07:15
Weekly Report: what happened at PROF last week (0323-0327)?
Weekly Report · 03/30 09:26
Profound Medical Marks Key TULSA Milestone as Texas Prostate Tops 100 Procedures
TipRanks · 03/27 13:53
More
About PROF
Profound Medical Corp. is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), AI-enhanced planning, robotically driven transurethral ultrasound and closed-loop temperature feedback control. The TULSA procedure, performed using the TULSA-PRO system, has the potential of becoming a mainstream treatment modality across the entire prostate disease spectrum; ranging from low-, intermediate-, or high-risk prostate cancer; to hybrid patients suffering from both prostate cancer and benign prostatic hyperplasia (BPH); to men with BPH only; and also, to patients requiring salvage therapy for radio-recurrent localized prostate cancer. It is also commercializing Sonalleve, a therapeutic platform that is CE marked for the treatment of uterine fibroids and palliative pain treatment of bone metastases.

Webull offers Profound Medical Corp stock information, including NASDAQ: PROF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PROF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PROF stock methods without spending real money on the virtual paper trading platform.